BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$22.88 USD
+0.79 (3.58%)
Updated Aug 6, 2024 04:00 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for BioLife Solutions, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 52 | 63 | 70 | 90 | 6 |
Receivables | 19 | 34 | 23 | 8 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 43 | 35 | 28 | 12 | 11 |
Other Current Assets | 7 | 7 | 4 | 5 | 1 |
Total Current Assets | 121 | 138 | 126 | 115 | 24 |
Net Property & Equipment | 21 | 24 | 18 | 10 | 6 |
Investments & Advances | 6 | 6 | 4 | 6 | 3 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 246 | 257 | 377 | 90 | 56 |
Deposits & Other Assets | 8 | 9 | 10 | 5 | 4 |
Total Assets | 413 | 450 | 554 | 235 | 93 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 15 | 15 | 4 | 3 |
Current Portion Long-Term Debt | 7 | 2 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 10 | 7 | 5 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 15 | 15 | 5 | 0 |
Total Current Liabilities | 42 | 45 | 40 | 16 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 5 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18 | 24 | 6 | 0 | 0 |
Non-Current Capital Leases | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 2 | 5 | 5 | 41 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 75 | 86 | 74 | 30 | 49 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 651 | 612 | 585 | 303 | 143 |
Retained Earnings | -313 | -247 | -105 | -97 | -100 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 338 | 364 | 480 | 205 | 43 |
Total Liabilities & Shareholder's Equity | 413 | 450 | 554 | 235 | 93 |
Total Common Equity | 338 | 364 | 480 | 205 | 43 |
Shares Outstanding | 44.00 | 42.70 | 40.70 | 32.70 | 20.40 |
Book Value Per Share | 7.67 | 8.53 | 11.80 | 6.28 | 2.13 |
Fiscal Year End for BioLife Solutions, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 45 | 52 | 41 | 46 |
Receivables | NA | 19 | 19 | 25 | 27 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 43 | 43 | 43 | 39 |
Other Current Assets | NA | 4 | 7 | 8 | 8 |
Total Current Assets | NA | 112 | 121 | 117 | 120 |
Net Property & Equipment | NA | 21 | 21 | 21 | 26 |
Investments & Advances | NA | 6 | 6 | 6 | 7 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 245 | 246 | 247 | 254 |
Deposits & Other Assets | NA | 7 | 8 | 8 | 10 |
Total Assets | NA | 402 | 413 | 411 | 433 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 7 | 12 | 11 |
Current Portion Long-Term Debt | NA | 9 | 7 | 5 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 12 | 9 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 13 | 13 | 14 | 14 |
Total Current Liabilities | NA | 39 | 42 | 43 | 40 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 16 | 18 | 21 | 24 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 0 | 0 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 68 | 75 | 79 | 81 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 659 | 651 | 633 | 623 |
Retained Earnings | NA | -325 | -313 | -300 | -271 |
Other Equity | NA | -1 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 333 | 338 | 332 | 352 |
Total Liabilities & Shareholder's Equity | NA | 402 | 413 | 411 | 433 |
Total Common Equity | 0 | 333 | 338 | 332 | 352 |
Shares Outstanding | 46.00 | 45.30 | 44.00 | 43.40 | 43.40 |
Book Value Per Share | 0.00 | 7.36 | 7.67 | 7.65 | 8.11 |